CA-LAMBDATEST
14.5.2024 19:01:37 CEST | Business Wire | Press release
LambdaTest, a leading cloud-based unified testing platform, is excited to announce its integration with BugHerd, the Australian-based website feedback and bug tracking tool. This collaboration is designed to enhance the efficiency of identifying and logging website bug reports during the testing phase.
BugHerd is a popular website bug-tracking tool that aids organizations by enabling them to easily create and collect bug reports, and track feedback. This streamlines communication by allowing clear pinpointing of issues, while also offering task management features to track bug progress and resolution within development teams.
This integration empowers users to effortlessly report bugs discovered during LambdaTest's comprehensive cross-browser testing sessions directly to their BugHerd project. With a single click, users can generate a new BugHerd task complete with essential details, including screenshots, browser, and operating system information, and the ability to assign the task to a specific team member. This eliminates the need for manual data entry and ensures all critical information is captured for efficient bug resolution.
Mayank Bhola, Co-Founder and Head of Product at LambdaTest, commented on the integration saying, "We're thrilled to offer this integration with BugHerd. It aligns perfectly with our mission to make the lives of testers and developers easier. By combining our efforts, we're simplifying the bug tracking process which is often a major bottleneck in web development."
Setting up the BugHerd integration is straightforward—users just need to enter their BugHerd API token in the LambdaTest settings. This simple step will connect their testing workflow directly to BugHerd, enabling them to start logging bugs immediately.
This new feature is designed to be seamless and easy to use, ensuring that even teams without technical expertise can efficiently enhance their web projects. Users can effortlessly manage their testing directly from LambdaTest and see their issues updated in BugHerd without any complications.
"This integration with LambdaTest underscores our commitment to agencies and web developers by allowing them to seamlessly link browser testing with direct feedback, thereby shortening project timelines and enhancing client satisfaction," said Stephen Neville, CEO of BugHerd.
This partnership between BugHerd and LambdaTest represents a significant step forward in making web testing more integrated and efficient, allowing development teams to deliver higher-quality websites faster and with fewer issues.
For more information about BugHerd’s integration with LambdaTest, please visit https://www.lambdatest.com/support/docs/bugherd-integration/
About LambdaTest
LambdaTest is an intelligent and omnichannel enterprise execution environment that helps businesses drastically reduce time to market through Just in Time Test Orchestration (JITTO), ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
- Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 3000+ different browsers, real devices, and operating system environments.
- HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to cut down on quality test time, helping developers build software faster.
For more information, please visit: https://lambdatest.com
About BugHerd
BugHerd is an Australian-based software company whose website feedback platform is used all around the world by creative and web development agencies, SaaS companies, education, and online learning organizations.
The company officially launched to the SaaS market in 2011 and was one of the first-ever Australian teams to grace the US-based startup program 500 Startups and the Australian-based Startmate.
BugHerd gained popularity by carving a niche in the Web Developer and Designer software tool market. It solved the difficulty they faced getting contextual website feedback from non-technical folk.
With Stephen Neville at the helm as CEO, the BugHerd team is committed to helping agencies run their website development projects to budget and on time, keeping their clients happy so that they come back for more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514577994/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom